+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rigel Pharmaceuticals Inc - logo

Rigel Pharmaceuticals is a clinical-stage biotechnology company that focuses on the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of a variety of diseases. It has been in trials for rheumatoid arthritis, autoimmune thrombocytopenia, lymphoma and others. In addition, Rigel also has two oncology product candidates in development. Founded in 1996, Rigel is headquartered in San Francisco, California.

Autoimmune Hemolytic Anemia Treatment - Global Strategic Business Report - Product Thumbnail Image

Autoimmune Hemolytic Anemia Treatment - Global Strategic Business Report

  • Report
  • July 2025
  • 465 Pages
  • Global
From
Hidradenitis Suppurativa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Hidradenitis Suppurativa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • February 2022
  • 106 Pages
  • Global
From
Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2025 - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 160 Pages
  • Global
From
Interleukin-1 (IL-1) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-1 (IL-1) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 925 Pages
  • Global
From
Rheumatoid Arthritis - Pipeline Review, H2 2020 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 1191 Pages
  • Global
From
RIPK1 Inhibitor - Pipeline Insights, 2025 - Product Thumbnail Image

RIPK1 Inhibitor - Pipeline Insights, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Thrombocytopenia - Market Insight, Epidemiology And Market Forecast - 2032 - Product Thumbnail Image

Thrombocytopenia - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • September 2022
  • 225 Pages
  • Global
From
Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 507 Pages
  • Global
From
Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 871 Pages
  • Global
From
Mayus Kinase 3 (JAK3) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Mayus Kinase 3 (JAK3) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 1560 Pages
  • Global
From
Collaboration Deals in Pharmaceuticals 2019-2025 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2019-2025

  • Report
  • April 2025
  • 950 Pages
  • Global
From
Cardiovascular Collaboration and Licensing Deals 2016-2025 - Product Thumbnail Image

Cardiovascular Collaboration and Licensing Deals 2016-2025

  • Report
  • April 2025
  • 300 Pages
  • Global
From
Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025 - Product Thumbnail Image

Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025

  • Report
  • April 2025
  • 550 Pages
  • Global
From
Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2025 - Product Thumbnail Image

Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2025

  • Report
  • April 2025
  • 450 Pages
  • Global
From
Glioma Treatment Market Report 2025 - Product Thumbnail Image

Glioma Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Distribution Deals in Pharmaceuticals and Biotechnology 2020-2025 - Product Thumbnail Image

Distribution Deals in Pharmaceuticals and Biotechnology 2020-2025

  • Report
  • April 2025
  • 300 Pages
  • Global
From
Loading Indicator